Fentanyl Transdermal Absorption Linked to Pharmacokinetic Characteristics in Patients Undergoing Palliative Care

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of clinical pharmacology

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270009347872PMID 20097932
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic reservoir and Durogesic D-Trans matrix transdermal fentanyl patches.

  2007cited by this paper
• Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.

  2005influential reference
• Inter- and Intraindividual Variabilities in Pharmacokinetics of Fentanyl After Repeated 72-Hour Transdermal Applications in Cancer Pain Patients

  2005cited by this paper
• Highly sensitive gas chromatographic-mass spectrometric screening method for the determination of picogram levels of fentanyl, sufentanil and alfentanil and their major metabolites in urine of opioid exposed workers.

  2004cited by this paper
• Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches.

  2004cited by this paper
• Benefit-Risk Assessment of Transdermal Fentanyl for the Treatment of Chronic Pain

  2003influential reference
• The Influence of Sex on Pharmacokinetics

  2003cited by this paper
• How Important Are Gender Differences in Pharmacokinetics?

  2002cited by this paper
• Transdermal fentanyl: little absorption in two patients with systemic sclerosis?

  2001cited by this paper
• Do Women Have More Adverse Drug Reactions?

  2001cited by this paper
• Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.

  2001cited by this paper
• Clinical Pharmacokinetics of Transdermal Opioids

  2000cited by this paper
• Pharmacokinetics of Opioids in Liver Disease

  1999cited by this paper
• Application of Physiologic Models to Predict the Influence of Changes in Body Composition and Blood Flows on the Pharmacokinetics of Fentanyl and Alfentanil in Patients

  1998cited by this paper
• Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

  1997cited by this paper
• Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.

  1996cited by this paper
• Clinical Pharmacokinetics of Alfentanil, Fentanyl and Sufentanil

  1996cited by this paper
• System functionality and physicochemical model of fentanyl transdermal system.

  1992cited by this paper
• Transdermally administered fentanyl for pain management.

  1992influential reference
• Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.

  1992cited by this paper
• Transdermally administered fentanyl for pain management.

  1992cited by this paper
• Variations in permeability of human skin within and between specimens

  1984cited by this paper
• Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis.

  1982cited by this paper

• Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug-drug interactions.

  2025cites this paper
• Biological sex differences in pharmacokinetics and adverse drug reactions

  2025cites this paper
• Is personal physiology-based rapid prediction digital twin for minimal effective fentanyl dose better than standard practice: a pilot study protocol

  2024cites this paper
• Gleich und doch verschieden – Personalisierte Schmerzmedizin

  2020cites this paper
• Fentanyl Pharmacokinetics : the role of clinical factors in patients with cancer using transdermal or sublingual fentanyl

  2019influential citation
• Does transdermal fentanyl work in patients with low BMI? Patient‐reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl

  2019cites this paper
• Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl

  2018cites this paper
• A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients

  2017cites this paper
• Maternal Epidural Fentanyl Administered for Labor Analgesia Is Found in Neonatal Urine 24 Hours After Birth

  2016cites this paper
• Reply to “Using postmortem blood and urine norfentanyl/fentanyl ratios in the investigation of fentanyl-related deaths”

  2016cites this paper
• Opioid metabolism and clinical aspects.

  2015cites this paper
• Alterations in drug disposition in older adults

  2015cites this paper
• An Examination of the Postmortem Redistribution of Fentanyl and Interlaboratory Variability ,

  2014cites this paper
• Alternative routes to oral opioid administration in palliative care: a review and clinical summary.

  2014cites this paper
• A simple liquid chromatography-tandem mass spectrometry method for determination of plasma fentanyl concentration in rats and patients with cancer pain.

  2013cites this paper
• Simple and rapid HPLC-UV method using an ultrafine particle octadecylsilane for determination of residual fentanyl in applied Durotep MT transdermal matrix patches and its clinical application.

  2012cites this paper
• Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system.

  2012cites this paper
• Factors Predicting Requirement of High-dose Transdermal Fentanyl in Opioid Switching From Oral Morphine or Oxycodone in Patients With Cancer Pain

  2011cites this paper
• Selecting an appropriate biomonitoring strategy to evaluate dermal exposure to opioid narcotic analgesics in pharmaceutical production workers

  2009cites this paper